Autoimmune Disease Testing Market Outlook: Size, Share, Trends, Growth Analysis, Competitive Landscape & Forecast, 2026-2033

North America Autoimmune Disease Testing Market

North America represents 38%–41% Autoimmune Disease Testing Market share in 2025 and is expected to grow at a CAGR of 10.8%–11.4% during 2026–2033. The region benefits from advanced healthcare infrastructure, strong presence of diagnostic companies, established reimbursement systems, and high adoption of automated laboratory technologies. Growing autoimmune disease awareness and increasing demand for precision diagnostics continue supporting market expansion across the United States and Canada.

• Advanced laboratory infrastructure supports widespread adoption of immunoassay and molecular diagnostic technologies.
• Rising autoimmune disease screening awareness encourages earlier testing and improved disease management.
• Strong research investments accelerate development of advanced biomarkers and diagnostic platforms.
• Healthcare providers increasingly adopt automated solutions to improve laboratory efficiency.

US Autoimmune Disease Testing Market

The United States accounts for 82%–85% of North American revenue and is projected to register a CAGR of 11.0%–11.6% during the forecast period. Strong diagnostic capabilities, favorable healthcare spending, and increasing demand for personalized medicine continue supporting market development.

• Growing prevalence of autoimmune conditions increases demand for routine and specialized testing.
• Leading diagnostic companies continue introducing advanced laboratory solutions across healthcare facilities.
• Reimbursement support improves accessibility to autoimmune testing procedures.
• Clinical research programs accelerate adoption of innovative biomarker-based diagnostics.

Europe Autoimmune Disease Testing Market

Europe holds 27%–30% market share in 2025 and is anticipated to expand at a CAGR of 10.5%–11.1% during 2026–2033. Strong healthcare systems, increasing chronic disease burden, and government support for diagnostic advancement continue driving regional demand. Germany remains the leading market, while France and the United Kingdom demonstrate steady growth through healthcare modernization and laboratory automation initiatives.

• European healthcare systems are increasing investment in advanced diagnostic infrastructure.
• Growing emphasis on early disease detection supports autoimmune testing adoption.
• Regulatory frameworks encourage development of reliable and accurate diagnostic technologies.
• Laboratory networks are expanding automated testing capabilities across hospitals and diagnostic centers.

Asia Pacific Autoimmune Disease Testing Market

Asia Pacific accounts for 24%–27% market share in 2025 and is expected to register the fastest 12.5%–13.2% CAGR through 2026–2033. Rising healthcare expenditure, expanding diagnostic centers, increasing disease awareness, and improving access to advanced medical technologies are supporting regional growth. China remains the largest contributor, while India and Southeast Asian countries demonstrate strong expansion potential.

• Healthcare infrastructure development is improving access to autoimmune testing services.
• Rising awareness campaigns encourage diagnosis of previously underidentified autoimmune conditions.
• Private diagnostic networks are expanding specialized testing capabilities.
• International companies are increasing investments in regional laboratory markets.

Rest of World Autoimmune Disease Testing Market

The Rest of World region contributes 6%–9% market share in 2025 and is projected to grow at a CAGR of 11.2%–11.8% during 2026–2033. Latin America, the Middle East, and Africa are experiencing gradual adoption due to healthcare modernization, improving diagnostic access, and rising awareness of autoimmune disorders.

• Brazil and Mexico are expanding diagnostic capabilities through healthcare investments.
• Middle Eastern countries are increasing adoption of advanced laboratory technologies.
• Healthcare partnerships are improving specialized testing availability in developing regions.
• Rising chronic disease awareness supports long-term demand for autoimmune diagnostics.

Product Type

The product type segment determines testing efficiency, accuracy, and scalability across hospitals, diagnostic laboratories, and research facilities. It accounted for 62%–65% market share in 2025 and is projected to grow at a CAGR of 11.7%–12.3% during 2026–2033. Increasing testing frequency, expanding diagnostic infrastructure, and continuous innovation in immunoassay technologies are supporting demand for advanced products. Growing Autoimmune Disease Testing Market trends indicate rising preference for automated systems and high-quality consumables that improve laboratory workflow and diagnostic reliability.

• Instruments: Instruments support automated testing processes by improving accuracy, reducing turnaround time, and enabling high-throughput autoimmune diagnostics across hospitals, laboratories, and specialized testing centers.
• Reagents & Consumables: Reagents and consumables represent the largest product category due to recurring demand for antibody tests, assay kits, calibration materials, and routine diagnostic procedures.

Disease Type

The disease type segment is expanding due to increasing recognition of autoimmune disorders and improved diagnostic capabilities for identifying disease-specific biomarkers. This segment accounted for 51%–54% market share in 2025 and is expected to achieve a CAGR of 11.3%–11.9% during 2026–2033. Growing clinical awareness, improved testing accuracy, and rising chronic disease prevalence are supporting wider adoption of specialized diagnostic solutions across healthcare settings.

• Rheumatoid Arthritis: Represents a major testing application due to high disease prevalence and continued demand for rheumatoid factor and antibody-based diagnostic evaluations.
• Systemic Lupus Erythematosus: Testing demand is increasing due to the complexity of disease symptoms and the need for accurate autoimmune marker identification.
• Scleroderma: Diagnostic requirements are expanding as healthcare providers utilize specialized antibody tests for early detection and improved disease management.
• Vasculitis: Growing adoption of autoimmune testing supports identification of inflammatory blood vessel disorders through advanced antibody and biomarker analysis.
• Inflammatory Bowel Disease: Increasing diagnosis rates are supporting demand for autoimmune-related testing solutions that assist in disease differentiation and treatment planning.

Test Type

The test type segment plays an important role in improving diagnostic precision by enabling identification of specific autoimmune markers and inflammatory responses. It represented 46%–49% market share in 2025 and is projected to grow at a CAGR of 11.6%–12.2% during 2026–2033. Advancements in immunological testing platforms and increasing demand for personalized treatment approaches are supporting expansion across clinical laboratories.

• Antinuclear Autoantibody: Widely used for autoimmune screening because it helps identify antibody patterns associated with multiple systemic autoimmune disorders.
• Rheumatoid Factor: Remains an important diagnostic marker for rheumatoid arthritis evaluation and supports disease monitoring through laboratory-based testing.
• C-Reactive Protein: Gains adoption as an inflammatory biomarker supporting assessment of disease activity and monitoring of inflammatory conditions.
• Anti-Thyroglobulin Antibody: Used in thyroid-related autoimmune disorder detection, supporting diagnosis and management of immune-mediated thyroid conditions.

End-user

The end-user segment is driven by increasing testing volumes across healthcare facilities, diagnostic networks, and specialized laboratories. It accounted for 45%–48% market share in 2025 and is anticipated to expand at a CAGR of 11.8%–12.4% during 2026–2033. Expansion of healthcare infrastructure, laboratory automation, and demand for faster diagnostic results continue improving adoption across different healthcare environments.

• Hospital & Clinics: Hospitals and clinics remain key users due to access to advanced diagnostic equipment, specialist consultations, and integrated patient management systems.
• Diagnostic Centers: Diagnostic centers are expanding rapidly through specialized testing services, automated laboratory platforms, and increasing outsourcing of complex autoimmune diagnostic procedures.